McKinsey November 23, 2021
Knut Alicke, Ed Barriball, and Vera Trautwein

Companies have only partly addressed the weaknesses in global supply chains exposed by the coronavirus pandemic. In the face of new challenges, finishing the job is even more urgent.
In May 2020, much of the world was still in the grip of the first wave of the COVID-19 pandemic. Lockdowns, shelter-in-place orders, and travel restrictions were disrupting activity in every part of the economy. Demand evaporated in some categories and skyrocketed in others. As they struggled to keep their businesses running, companies were planning significant strategic changes to the configuration and operation of their supply chains. When we surveyed senior supply-chain executives from across industries...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Health System / Hospital, Healthcare System, Provider, Public Health / COVID, Supply Chain, Technology
AstraZeneca plans independent drug supply chains for US and China, CEO says
Vitality in the Supply Chain: The Limitless Potential of ATMPs
Red Sea Shipping Disruptions Don’t Have Pharma Companies Seeing Red Just Yet
Managing Uncertainties In Cell And Gene Therapy Supply Chain
Supply chain trends and challenges: Cell and gene therapies

Share This Article